CDK5 inhibition in�vitro and in vivo induces cell death in�myeloma and overcomes the obstacle of bortezomib resistance-Reference-Cited by-同舟云学术

CDK5 inhibition in�vitro and in vivo induces cell death in�myeloma and overcomes the obstacle of bortezomib resistance

Published:2020-03-26 Issue: Volume: Page:
ISSN:1107-3756
Container-title:International Journal of Molecular Medicine
language:
Short-container-title:Int J Mol Med

Author:

Tang Hailong¹,Xu Li¹,Cen Xi²,Yang Li³,Feng Juan¹,Li Guang¹,Zhu Huafeng¹,Gao Shan¹,Yu Yan¹,Zhao Yaping¹,Tian Zhiqiang¹,Hou Liping¹,Yu Shuchun¹,Gao Guangxun¹

Affiliation:

1. Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China

2. Department of Public Health Sciences, University of Rochester, Rochester, NY 14642, USA

3. Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China

Publisher

Spandidos Publications

Subject

Genetics,General Medicine

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK5 as a therapeutic tool for the treatment of Alzheimer's disease: A review;European Journal of Pharmacology;2024-09

2. Cyclin‐dependent kinase 5 (CDK5) inhibitors in Parkinson disease;Journal of Cellular and Molecular Medicine;2024-06

3. CDK5: an oncogene or an anti-oncogene: location location location;Molecular Cancer;2023-11-23

4. A review on cyclin-dependent kinase 5: An emerging drug target for neurodegenerative diseases;International Journal of Biological Macromolecules;2023-03

5. Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors;Journal of Experimental & Clinical Cancer Research;2022-08-15